' /> ' /> ' />
A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Intensive Course in Cancer Risk Assessment Overview Bookmark and Share

Intensive Course in Cancer Risk Assessment Overview

To help address the growing demand for clinicians with interdisciplinary knowledge and skills in the practice of genetic cancer risk assessment (GCRA), the multifaceted Intensive Course in Cancer Risk Assessment and its Clinical Cancer Genetics Community of Practice (CCGCoP) leverage the expertise of the academic health center through Web-based tools to deliver accessible, evidence-based cancer genetics and genomics training, professional development, and practice-centered support at the point of care. The mission of the Intensive Course and CCGCoP is to increase the number of clinicians who are able to translate rapid advances in genetics and genomics into cancer risk assessment, management, and prevention practice. Realizing the promise of personalized medicine by promoting best practices in the delivery of GCRA services across the U.S. and internationally is the ultimate goal of the Clinical Cancer Genetics Community of Practice.
 
 
Objectives
 
At the conclusion of the course the participants should be able to:
  • Integrate cancer genetics and oncology knowledge into clinical practice
  • Apply skills commensurate with practitioner-level proficiency into the cancer risk assessment and case management process
  • Recommend risk-appropriate options for cancer surveillance and prevention as part of the cancer risk assessment, including imaging, chemo preventive and surgical interventions
  • Incorporate understanding of medical, legal, and psychosocial ramifications of cancer risk counseling and testing into clinical practice and research collaboration
  • Discuss clinical research methodologies in cancer genetics epidemiology and cancer prevention trials for high-risk cohorts
  • Recognize the roles and practical issues related to Human Subjects Protections, Informed Consent, Institutional Review Board and HIPAA in clinical research
  • Provide resources and information on current hereditary cancer registries, cancer epidemiology and cancer prevention studies to patients and professional colleagues
  • Use research training and support to participate in collaborative research activities
  • Realize greater professional self-efficacy related to cancer risk counseling and research participation skills
  • Incorporate web-based resources into ongoing practice-based education, professional development and research network support
 
 
Reaching Clinicians Around the Globe
 
City of Hope's Intensive Course in Cancer Risk Assessment has trained health care professionals in community settings across the United States as well as in Argentina, Brazil, Canada, Chile, Columbia, Germany, Hong Kong, Mexico, Peru, Philippines, Puerto Rico, Spain, Taiwan, Turkey, and Uruguay. Genetics on last line is misspelled. Participation of the Intensive Course alumni in the ongoing practice-centered professional development activities hosted by City of Hope has evolved into a dynamic international Clinical Cancer Genetics Community of Practice.
 
 

Accreditation

CME Credits
Accreditation Statement: Accreditation in process

Credit Designation: City of Hope designates this educational activity for a maximum of (TBD) AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The following may apply CME Category 1 credit for license renewal:

Registered Nurses: Nurses may report up to (TBD) credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number.

Physician’s Assistants: The National Commission on Certification of Physician Assistants states that AMA accredited Category 1 courses are acceptable for CME requirements for recertification.

Genetic Counselor CEUs: The American Board of Genetic Counseling (ABGC) accepts CEUs approved by the National Society for Genetic Counselors (NSGC) for purposes of recertification. This event has been submitted to NSGC for approval of Category 1 CEUs and is approved for (TBD) CEUs and (TBD) Contact Hours.

Disclosure
The City of Hope adheres to ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control content of an educational activity will be made at the activity. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
 
No partial credit will be given. Participants should claim only those hours of credit that they actually spent at the educational activity.
 

Intensive Course Application Requirement

Click image to apply.
Application Deadline
 
Enrollment for the 2015 Winter course will begin on June 20, 2014. The deadline will be August 1, 2014.
 
Requirements
Please read all terms stated below before submitting application.

To receive full course credit, and certificate of course completion, course participants will be required to:
 
  • Participate in all distance and on-campus course related activities.
  • Complete all distance learning lecture modules delivered via Website and USB drive (flashdrive) interface by given deadlines.
  • Complete all pre- and post-course surveys, knowledge questionnaires, evaluations, and assignments as directed.
  • Agree to complete prescribed post-course professional development activities as outlined in the course syllabus. Some activities are required to be completed at 6-months post training and some must be completed by 1-year post training.
 
Selection Criteria
Preferred candidates are oncology or genetics-trained physicians, advanced practice nurses and genetic counselors currently providing or planning to initiate community-based clinical cancer genetics services.
 
 
How to Apply
 
Complete the Intensive Course Application and submit the following:
 
  • Completed application form
  • Letter from your institution indicating that protected time will be provided for course participation, and statement that you will have institutional support to provide cancer risk assessment upon return to your community (if applicable).
  • Current curriculum vitae (CV)
  • Mini-biography
  • Current headshot
 
Please NOTE: Applications will not be accepted without the items listed above.
 
Submit all of the above via regular mail, email or fax to:
 
Gloria Nuñez, Conference Coordinator
City of Hope
Division of Clinical Cancer Genetics, Mod 173
1500 East Duarte Road
Duarte, CA 91010-3000

Fax:
626-930-5495

Email:
gnunez@coh.org (note subject as "Intensive Course")
 
Acceptance
Applicants will be notified of acceptance by September 30, 2014, via e-mail. The non-refundable course fee (TBD) will be due on or before October 31, 2014.
 

Faculty

Course Co-directors
Jeffrey Weitzel, M.D.
Director, Division of Clinical Cancer Genetics
and
Kathleen R. Blazer, Ed.D., M.S., L.C.G.C.
Assistant Director, Cancer Genetics Education Program

City of Hope Faculty
Danielle Castillo, BS
Cathy Cole, RNC, NP, MPH
Josef Herzog, BS
Robert Morgan, Jr., MD, FACP
Bita Nehoray, MS, LCGC
Mariana Niell-Swiller, MS, CGC
Lacolle Robinson, BA
Sharon Sand, BA, CCRP
Ilana Solomon, ScM, MS, CGC
April Sorrell, MD
Sharon Wilczynski, MD, PhD

Guest Faculty
Kimberly Banks, MS, CGC, Ambry Genetics
Julie Culver, MS, LCGC, USC Norris Comprehensive Cancer Center
Allan Ebbin, MD, MPH, UnitedHealthcare (retired)
Carin Espenschied, MS, LCGC, Ambry Genetics
Carol Fabian, MD, University of Kansas Cancer Breast Cancer Prevention and Survivorship Centers
Lucille Leong, MD, City of Hope
Katrina Lowstuter, MS, CGC, USC Norris Comprehensive Cancer Center
Deborah J. MacDonald, PhD, RN, APNG, (former CCG faculty)
Hazel Mariveles, BS, (former CCG staff)
Susan Neuhausen, PhD, University of California Irvine
Gloria Petersen, PhD, Mayo Clinic
Charité Ricker, MS, CGC, LAC+USC Medical Center

Administrative Staff
Gloria Nuñez, Conference Coordinator
Stacy Berger, Programmer Analyst
Larry Kiang, Technology Specialist
Tracy Sulkin, Education Assistant

Intensive Course Alumni

City of Hope's Intensive Course in Cancer Risk Assessment has trained health professionals in community settings across the United States as well as in Argentina, Brazil, Canada, Chile, Columbia, Germany, Hong Kong, Mexico, Peru, Philippines, Puerto Rico, Spain, Taiwan, Turkey, and Uruguay.

Intensive Course Description

The Intensive Course and Clinical Cancer Genetics Community of Practice embody the tenets of practice-centered situated learning theory. Distance delivery of a modular curriculum responds to the practical time constraints of working clinicians and allows for flexible, self-directed study (e.g., oncologists can opt out of basic oncology content and focus more study time on genetics content, etc.). Concurrent participation in Working Group Clinical Cancer Genetics Web conferences reinforces didactic learning and Genetic Cancer Risk Assessment (GCRA) skills development. Participants have the option of participating in one of four training tracks to customize training to meet their learning needs.
 
 
Click the individual track link below for more information, including fees, and to download the track Calendar for 2015 Winter (calendar in progress).
 
 
All four tracks include distance didactic learning with corresponding Web conference reviews, and case-based training with Working Group Web conferences. Only Track 1 Full Spectrum Multi-modal Training includes four days of face-to-face program development workshops.
 
Upon completion of training, all participants receive support to apply new learning to practice through 12 months of self-directed engagement and activities as members of the Clinical Cancer Genetics Community of Practice.
 
 
 

Intensive Course Track 2--Full Spectrum Distance-only Training

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 14, 2014, (8:00-11:00 a.m. PT), and
 
(b) Complete 12 weeks of Distance Learning Modules with weekly Live Web-based discussion sessions every Friday morning (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 14, 2014 through February 20, 2015
 
Phase 2: (no on-campus workshops)
 

Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before November 3, 2014)

MDs:  $1,600
RNs/GCs/Fellows/Pa-Cs:  $1,200
Industry:  $2,600
(Fees do not including travel or hotel)
 
 

Apply now: Intensive Course Application 2015 (The deadline to apply is August 1, 2014.)
 
 

Intensive Course Track 1: Full Spectrum Multi-modal Training

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 14, 2014, (8:00-11:00 a.m. PT), and
 
(b) Complete 12 weeks of Distance Learning Modules with weekly Live Web-based discussion sessions every Friday morning (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 14, 2014 through February 20, 2015
 
Phase 2:

Four days of face-to-face Cancer Genetics Workshops on-campus at City of Hope in Duarte, CA.
 
Dates:  February 23 - 26, 2015
 
Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before November 3, 2014)

MDs:  $2,000
RNs/GCs/Fellows/Pa-Cs:  $1,600
Industry:  $3,000
(Fees do not including travel or hotel)
 

Apply now:  Intensive Course Application 2015 (The deadline to apply is August 1, 2014.)
 
 

IC Tracks 3 & 4-Breast-Ovarian OR GI Sub-specialty Distance-only

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 14, 2014, (8:00-11:00 a.m. PT), and
 
(b) Complete Distance Learning Modules (subset of full curriculum delivered over 12 weeks with Live Web-based discussion sessions Friday mornings (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 14, 2014 through February 20, 2015
 
Phase 2: (no on-campus workshops)
 
Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before November 3, 2014)

MDs:  $1,600
RNs/GCs/Fellows/Pa-Cs:  $1,200
Industry:  $2,600
(Fees do not including travel or hotel)
 
 

Apply now:  Intensive Course Application 2015 (The deadline to apply is August 1, 2014.)
 
 
 
 

Clinical Cancer Genetics Community of Practice

City of Hope Clinical Cancer Genetics Community of Practice brings cancer genetics practitioners from diverse practice settings together for professional learning, enduring patient-centered support and dynamic community-based research collaborations to promote quality care and improved patient outcomes across the U.S. and internationally.
 
Working Group
 
Clinical Cancer Genetics (CCG) Working Group is a CME-accredited interdisciplinary cancer genetics case conference series conducted each week by the City of Hope clinical team.
 
TICGR Topics in Cancer Genetics Research
 
Topics in Clinical Cancer Genetics (TICGR) is a weekly one-hour CME-accredited web-conference seminar series focused on timely issues in clinical cancer genetics, cancer epidemiology and cancer genetics research, alternating between didactic lectures, case-based literature reviews and basic research journal club.
 

A Web-based discussion board for collaborative, interdisciplinary practice-based support and continuing professional learning.
 
Knowledge Center
 
Knowledge Center Information coming soon
 

A large research group of over 40 collaborating sites in the 40 collaborating sites in the United States, Mexico, and South America. As members of the CCGCRN, research collaborators can use the message board and forums to post questions and communicate with other members in the network.
 

Intensive Course in Cancer Risk Assessment Overview

Intensive Course in Cancer Risk Assessment Overview

To help address the growing demand for clinicians with interdisciplinary knowledge and skills in the practice of genetic cancer risk assessment (GCRA), the multifaceted Intensive Course in Cancer Risk Assessment and its Clinical Cancer Genetics Community of Practice (CCGCoP) leverage the expertise of the academic health center through Web-based tools to deliver accessible, evidence-based cancer genetics and genomics training, professional development, and practice-centered support at the point of care. The mission of the Intensive Course and CCGCoP is to increase the number of clinicians who are able to translate rapid advances in genetics and genomics into cancer risk assessment, management, and prevention practice. Realizing the promise of personalized medicine by promoting best practices in the delivery of GCRA services across the U.S. and internationally is the ultimate goal of the Clinical Cancer Genetics Community of Practice.
 
 
Objectives
 
At the conclusion of the course the participants should be able to:
  • Integrate cancer genetics and oncology knowledge into clinical practice
  • Apply skills commensurate with practitioner-level proficiency into the cancer risk assessment and case management process
  • Recommend risk-appropriate options for cancer surveillance and prevention as part of the cancer risk assessment, including imaging, chemo preventive and surgical interventions
  • Incorporate understanding of medical, legal, and psychosocial ramifications of cancer risk counseling and testing into clinical practice and research collaboration
  • Discuss clinical research methodologies in cancer genetics epidemiology and cancer prevention trials for high-risk cohorts
  • Recognize the roles and practical issues related to Human Subjects Protections, Informed Consent, Institutional Review Board and HIPAA in clinical research
  • Provide resources and information on current hereditary cancer registries, cancer epidemiology and cancer prevention studies to patients and professional colleagues
  • Use research training and support to participate in collaborative research activities
  • Realize greater professional self-efficacy related to cancer risk counseling and research participation skills
  • Incorporate web-based resources into ongoing practice-based education, professional development and research network support
 
 
Reaching Clinicians Around the Globe
 
City of Hope's Intensive Course in Cancer Risk Assessment has trained health care professionals in community settings across the United States as well as in Argentina, Brazil, Canada, Chile, Columbia, Germany, Hong Kong, Mexico, Peru, Philippines, Puerto Rico, Spain, Taiwan, Turkey, and Uruguay. Genetics on last line is misspelled. Participation of the Intensive Course alumni in the ongoing practice-centered professional development activities hosted by City of Hope has evolved into a dynamic international Clinical Cancer Genetics Community of Practice.
 
 

Accreditation

Accreditation

CME Credits
Accreditation Statement: Accreditation in process

Credit Designation: City of Hope designates this educational activity for a maximum of (TBD) AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The following may apply CME Category 1 credit for license renewal:

Registered Nurses: Nurses may report up to (TBD) credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number.

Physician’s Assistants: The National Commission on Certification of Physician Assistants states that AMA accredited Category 1 courses are acceptable for CME requirements for recertification.

Genetic Counselor CEUs: The American Board of Genetic Counseling (ABGC) accepts CEUs approved by the National Society for Genetic Counselors (NSGC) for purposes of recertification. This event has been submitted to NSGC for approval of Category 1 CEUs and is approved for (TBD) CEUs and (TBD) Contact Hours.

Disclosure
The City of Hope adheres to ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control content of an educational activity will be made at the activity. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
 
No partial credit will be given. Participants should claim only those hours of credit that they actually spent at the educational activity.
 

Application Requirement

Intensive Course Application Requirement

Click image to apply.
Application Deadline
 
Enrollment for the 2015 Winter course will begin on June 20, 2014. The deadline will be August 1, 2014.
 
Requirements
Please read all terms stated below before submitting application.

To receive full course credit, and certificate of course completion, course participants will be required to:
 
  • Participate in all distance and on-campus course related activities.
  • Complete all distance learning lecture modules delivered via Website and USB drive (flashdrive) interface by given deadlines.
  • Complete all pre- and post-course surveys, knowledge questionnaires, evaluations, and assignments as directed.
  • Agree to complete prescribed post-course professional development activities as outlined in the course syllabus. Some activities are required to be completed at 6-months post training and some must be completed by 1-year post training.
 
Selection Criteria
Preferred candidates are oncology or genetics-trained physicians, advanced practice nurses and genetic counselors currently providing or planning to initiate community-based clinical cancer genetics services.
 
 
How to Apply
 
Complete the Intensive Course Application and submit the following:
 
  • Completed application form
  • Letter from your institution indicating that protected time will be provided for course participation, and statement that you will have institutional support to provide cancer risk assessment upon return to your community (if applicable).
  • Current curriculum vitae (CV)
  • Mini-biography
  • Current headshot
 
Please NOTE: Applications will not be accepted without the items listed above.
 
Submit all of the above via regular mail, email or fax to:
 
Gloria Nuñez, Conference Coordinator
City of Hope
Division of Clinical Cancer Genetics, Mod 173
1500 East Duarte Road
Duarte, CA 91010-3000

Fax:
626-930-5495

Email:
gnunez@coh.org (note subject as "Intensive Course")
 
Acceptance
Applicants will be notified of acceptance by September 30, 2014, via e-mail. The non-refundable course fee (TBD) will be due on or before October 31, 2014.
 

Faculty

Faculty

Course Co-directors
Jeffrey Weitzel, M.D.
Director, Division of Clinical Cancer Genetics
and
Kathleen R. Blazer, Ed.D., M.S., L.C.G.C.
Assistant Director, Cancer Genetics Education Program

City of Hope Faculty
Danielle Castillo, BS
Cathy Cole, RNC, NP, MPH
Josef Herzog, BS
Robert Morgan, Jr., MD, FACP
Bita Nehoray, MS, LCGC
Mariana Niell-Swiller, MS, CGC
Lacolle Robinson, BA
Sharon Sand, BA, CCRP
Ilana Solomon, ScM, MS, CGC
April Sorrell, MD
Sharon Wilczynski, MD, PhD

Guest Faculty
Kimberly Banks, MS, CGC, Ambry Genetics
Julie Culver, MS, LCGC, USC Norris Comprehensive Cancer Center
Allan Ebbin, MD, MPH, UnitedHealthcare (retired)
Carin Espenschied, MS, LCGC, Ambry Genetics
Carol Fabian, MD, University of Kansas Cancer Breast Cancer Prevention and Survivorship Centers
Lucille Leong, MD, City of Hope
Katrina Lowstuter, MS, CGC, USC Norris Comprehensive Cancer Center
Deborah J. MacDonald, PhD, RN, APNG, (former CCG faculty)
Hazel Mariveles, BS, (former CCG staff)
Susan Neuhausen, PhD, University of California Irvine
Gloria Petersen, PhD, Mayo Clinic
Charité Ricker, MS, CGC, LAC+USC Medical Center

Administrative Staff
Gloria Nuñez, Conference Coordinator
Stacy Berger, Programmer Analyst
Larry Kiang, Technology Specialist
Tracy Sulkin, Education Assistant

Intensive Course Alumni

Intensive Course Alumni

City of Hope's Intensive Course in Cancer Risk Assessment has trained health professionals in community settings across the United States as well as in Argentina, Brazil, Canada, Chile, Columbia, Germany, Hong Kong, Mexico, Peru, Philippines, Puerto Rico, Spain, Taiwan, Turkey, and Uruguay.

Intensive Course Description

Intensive Course Description

The Intensive Course and Clinical Cancer Genetics Community of Practice embody the tenets of practice-centered situated learning theory. Distance delivery of a modular curriculum responds to the practical time constraints of working clinicians and allows for flexible, self-directed study (e.g., oncologists can opt out of basic oncology content and focus more study time on genetics content, etc.). Concurrent participation in Working Group Clinical Cancer Genetics Web conferences reinforces didactic learning and Genetic Cancer Risk Assessment (GCRA) skills development. Participants have the option of participating in one of four training tracks to customize training to meet their learning needs.
 
 
Click the individual track link below for more information, including fees, and to download the track Calendar for 2015 Winter (calendar in progress).
 
 
All four tracks include distance didactic learning with corresponding Web conference reviews, and case-based training with Working Group Web conferences. Only Track 1 Full Spectrum Multi-modal Training includes four days of face-to-face program development workshops.
 
Upon completion of training, all participants receive support to apply new learning to practice through 12 months of self-directed engagement and activities as members of the Clinical Cancer Genetics Community of Practice.
 
 
 

Schedule

Full Spectrum Distance-only Training

Intensive Course Track 2--Full Spectrum Distance-only Training

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 14, 2014, (8:00-11:00 a.m. PT), and
 
(b) Complete 12 weeks of Distance Learning Modules with weekly Live Web-based discussion sessions every Friday morning (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 14, 2014 through February 20, 2015
 
Phase 2: (no on-campus workshops)
 

Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before November 3, 2014)

MDs:  $1,600
RNs/GCs/Fellows/Pa-Cs:  $1,200
Industry:  $2,600
(Fees do not including travel or hotel)
 
 

Apply now: Intensive Course Application 2015 (The deadline to apply is August 1, 2014.)
 
 

Full Spectrum Multi-modal Training

Intensive Course Track 1: Full Spectrum Multi-modal Training

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 14, 2014, (8:00-11:00 a.m. PT), and
 
(b) Complete 12 weeks of Distance Learning Modules with weekly Live Web-based discussion sessions every Friday morning (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 14, 2014 through February 20, 2015
 
Phase 2:

Four days of face-to-face Cancer Genetics Workshops on-campus at City of Hope in Duarte, CA.
 
Dates:  February 23 - 26, 2015
 
Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before November 3, 2014)

MDs:  $2,000
RNs/GCs/Fellows/Pa-Cs:  $1,600
Industry:  $3,000
(Fees do not including travel or hotel)
 

Apply now:  Intensive Course Application 2015 (The deadline to apply is August 1, 2014.)
 
 

Breast-Ovarian OR G.I. Sub-specialty Training

IC Tracks 3 & 4-Breast-Ovarian OR GI Sub-specialty Distance-only

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 14, 2014, (8:00-11:00 a.m. PT), and
 
(b) Complete Distance Learning Modules (subset of full curriculum delivered over 12 weeks with Live Web-based discussion sessions Friday mornings (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 14, 2014 through February 20, 2015
 
Phase 2: (no on-campus workshops)
 
Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before November 3, 2014)

MDs:  $1,600
RNs/GCs/Fellows/Pa-Cs:  $1,200
Industry:  $2,600
(Fees do not including travel or hotel)
 
 

Apply now:  Intensive Course Application 2015 (The deadline to apply is August 1, 2014.)
 
 
 
 

CCG Community of Practice

Clinical Cancer Genetics Community of Practice

City of Hope Clinical Cancer Genetics Community of Practice brings cancer genetics practitioners from diverse practice settings together for professional learning, enduring patient-centered support and dynamic community-based research collaborations to promote quality care and improved patient outcomes across the U.S. and internationally.
 
Working Group
 
Clinical Cancer Genetics (CCG) Working Group is a CME-accredited interdisciplinary cancer genetics case conference series conducted each week by the City of Hope clinical team.
 
TICGR Topics in Cancer Genetics Research
 
Topics in Clinical Cancer Genetics (TICGR) is a weekly one-hour CME-accredited web-conference seminar series focused on timely issues in clinical cancer genetics, cancer epidemiology and cancer genetics research, alternating between didactic lectures, case-based literature reviews and basic research journal club.
 

A Web-based discussion board for collaborative, interdisciplinary practice-based support and continuing professional learning.
 
Knowledge Center
 
Knowledge Center Information coming soon
 

A large research group of over 40 collaborating sites in the 40 collaborating sites in the United States, Mexico, and South America. As members of the CCGCRN, research collaborators can use the message board and forums to post questions and communicate with other members in the network.
 
Clinical Cancer Genetics
The City of Hope Division of Clinical Cancer Genetics is committed to being a national leader in the advancement of cancer genetics, screening and prevention, through innovative patient care, research and education.

Contact Us
  • 800-826-HOPE (4673)
  • For more information about the Cancer Screening & Prevention Program, call 626-256-8662, ext. 2.
CCG Newsletter: Closing the Loop
View the current issue: CCG 2013 Newsletter 7-14-14
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
NEWS & UPDATES
  • Thyroid cancer has become one of the fastest-growing cancers in the United States for both men and women. The chance of being diagnosed with the cancer has nearly doubled since 1990. This year an estimated 63,000 people will be diagnosed with thyroid cancer in the United States and nearly 1,900 people will die ...
  • Older teenagers and young adults traditionally face worse outcomes than younger children when diagnosed with brain cancer and other central nervous system tumors. A first-of-its-kind study shows why. A team of researchers from the departments of Population Sciences and Pathology at City of Hope recently examine...
  • Cancer treatment can take a toll on the mouth, even if a patient’s cancer has nothing to do with the head or throat, leading to a dry mouth, or a very sore mouth, and making it difficult to swallow or eat. Here’s some advice from the National Cancer Institute (NCI)  on how to ease cancer-related dis...
  • Radiation oncology is one of the three main specialties involved in the successful treatment of cancer, along with surgical oncology and medical oncology. Experts in this field, known as radiation oncologists, advise patients as to whether radiation therapy will be useful for their cancer – and how it can best ...
  • There’s more to cancer care than simply helping patients survive. There’s more to cancer treatment than simple survival. Constant pain should not be part of conquering cancer,  insists Betty Ferrell, Ph.D., R.N., director of nursing research and education at City of Hope. She wants patients and caregivers...
  • Even its name is daunting. Systemic mastocytosis is a fatal disease of the blood with no known cure. But a new study suggests a bone marrow transplant may be the answer for some patients. While rare, systemic mastocytosis is resistant to treatment with drugs and, when aggressive, can be fatal within four years ...
  • Could what you eat affect the health of your chromosomes? The short answer is, “Yes.” Researchers led by Dustin Schones, Ph.D., assistant professor in the Department of Cancer Biology, and Rama Natarajan, Ph.D., director of the Division of Molecular Diabetes Research and the National Business Products Industry ...
  • September is Prostate Cancer Awareness Month. Here, Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope, explains the importance of understanding the risk factors for the disease and ways to reduce those risks, as well as overall prostate health. “Wha...
  • ** Learn more about prostate health, plus prostate cancer research and treatment, at City of Hope. ** Learn more about getting a second opinion at City of Hope by visiting us online or by calling 800-826-HOPE (4673). City of Hope staff will explain what’s required for a consult at City of Hope and help yo...
  • Childhood cancer survival rates have increased dramatically over the past 40 years. More than 80 percent of children with cancer now survive five years or more, which is a tremendous feat. Despite the survival rate increase, cancer continues to be the No. 1 disease killer and second-leading cause of death in ch...
  • Although a stem cell transplant can be a lifesaving procedure for people diagnosed with a blood cancer or blood disorder, the standard transplant may not be appropriate for all patients. This is because the conditioning regimen (the intensive chemotherapy and/or radiation treatments preceding the transplant) is...
  • Brain tumor removal would seem to be the obvious course of action in the wake of a brain tumor diagnosis, but that’s not always the case. Some tumors are too difficult for many surgeons to reach or too close to areas that control vital functions. Removing them just proves too risky. A new device being con...
  • Hijacking the same sorts of viruses that cause HIV and using them to reprogram immune cells to fight cancer sounds like stuff of the future. Some scientists believe that the future is closer than we think – and are now studying the approach in clinical trials at City of Hope. Immunotherapy is a promising approa...
  • Jennifer Linehan, M.D., an assistant clinical professor in City of Hope’s Division of Urology and Urologic Oncology in Antelope Valley, thought she knew all there was to know about treating prostate cancer. Then her father was diagnosed with the disease. This is her story. ** My father is 69 years old, has no h...
  • Nausea is the one of the most well-known, and dreaded, side effects of cancer treatment — and with good reason. Beyond the quality-of-life issues that it causes, severe nausea can prevent patients from receiving enough nutrients and calories at a time when they need every edge they can get. A few simple actions...